You searched for Retinitis pigmentosa

News and Trends 7 Feb 2023

Endogena Therapeutics retinitis pigmentosa treatment gets FDA fast track designation

The US Food and Drug Administration (FDA) has designated the investigation of Endogena Therapeutics’ EA-2353 for the treatment of retinitis pigmentosa (RP) as a fast track development program. Fast track is a process designed to enable patients to benefit earlier from new drugs for serious conditions. Endogena Therapeutics’ EA-2353 takes a novel, small-molecule approach and […]

February 7, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 10 Oct 2022

Fast track designation for Nanoscope Therapeutics’ retinitis pigmentosa treatment

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, says the U.S. Food and Drug Administration (FDA) has granted fast track designation (FTD) to MCO-010. MCO-010 is an ambient-light activatable multi-characteristic opsin (MCO) optogenetic monotherapy to restore vision in blind patients, for the treatment of retinitis pigmentosa (RP) via intravitreal […]

October 10, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 12 Jul 2022

Endogena Therapeutics to start clinical stage with treatment for blindness caused by retinitis pigmentosa

Endogena Therapeutics Inc. has announced the first patient has been treated in a phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP). RP is a group of inherited diseases causing slow and progressive retinal degeneration and loss of vision, for which there is currently no treatment for […]

July 12, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 18 Sep 2018

Update: French Biotech Raises €22M for a Gene Therapy Trial in Retinitis Pigmentosa

Update (18/09/2018): Horama has increased the total raised in its Series B fundraising to €22.5M, with the Belgian fund V-Bio Ventures joining the team of investors backing the company. The funds will be mainly directed at developing Horama’s gene therapy for retinitis pigmentosa. Published on 08/10/2017 Horama has raised a second fundraising round that will support […]

September 18, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Retinitis pigmentosa gene therapy Horama

News and Trends 11 Jul 2018

Gene Therapy for Retinitis Pigmentosa Tested in Humans for the First Time

French biotech Horama has treated the first patients with a gene therapy for retinitis pigmentosa that could prevent the progressive loss of vision caused by this genetic condition. A Phase I/II trial with Horama’s gene therapy for retinitis pigmentosa is running at the Nantes University Hospital. The therapy is aimed at fixing genetic defects in a […]

July 11, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 24 Jan 2018

New Retinitis Pigmentosa Treatments? This Blood-Retina Chip Could Help!

A new ‘organ-on-a-chip’ device for the blood-retina barrier could speed up the development of treatments for eye diseases like retinitis pigmentosa. Researchers from Microelectronics Institute of Barcelona, Vall d’Hebron Research Institute, and Universitat Autònoma de Barcelona have developed a microfluidic chip that mimics the human blood-retinal barrier in the eye. The study, published in Lab on a […]

January 24, 2018 - 3 minutesmins - By Alex Dale

gensight retinitis pigmentosa gene therapy

News and Trends 10 Jan 2018

French Biotech Starts Trials to Restore Sight in All Types of Retinitis Pigmentosa

GenSight will start a clinical trial in the UK testing a combination of gene therapy and a wearable device to restore sight in patients with retinitis pigmentosa. The UK Medicines and Healthcare Regulatory Agency (MHRA) has accepted GenSight’s application to run a first clinical trial in the UK testing a new type of therapy with the […]

January 10, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Oct 2017

French Gene Therapy to Cure Retinitis Pigmentosa Enters the Clinic

Horama has been authorized to start a Phase I/II trial in France testing HORA-PDE6B, a one-off gene therapy with the potential to cure retinitis pigmentosa. Based in Paris, Horama develops gene therapies to treat genetic diseases affecting vision. The company will now start a Phase I/II clinical trial that will recruit 12 patients at the Nantes […]

October 11, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 27 Feb 2024

Japan’s ten hottest biotech companies in healthcare

While Japan historically lacked foreign investment the field is becoming more dynamic. Discover ten essential biotech companies in Japan.

February 27, 2024 - 12 minutesmins - By Jules Adam

Best in Biotech 22 Feb 2024

10 gene therapy companies you should know about

Explore 10 gene therapy companies operating within the biotech industry, as each one hopes to develop their own novel candidates.

February 22, 2024 - 13 minutesmins - By Willow Shah-Neville

Best in Biotech 23 Jan 2024

19 French biotechs you should know about

France is at the forefront of innovative biotech and Paris has become a vibrant startup ecosystem. Here are 19 top French biotech companies!

January 23, 2024 - 22 minutesmins - By Jules Adam

Weekly Roundup 15 Dec 2023

Pharvaris’ $300 million public offering; Genentech’s breast cancer trial success; new neuromuscular disease target discovered

What’s been going on in the world of biotech of late? Find out with Labiotech’s weekly roundup of the latest biotech news.

December 15, 2023 - 14 minutesmins - By Roohi Mariam Peter

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us